Dual antigen-targeting protein complex comprising antibody or antigen-binding fragment thereof and affibody

A dual antigen targeting protein complex combining antibodies and affibodies effectively targets multiple cancer antigens, overcoming the limitations of monotherapy by enhancing binding affinity and anticancer effects, particularly in cancers with complex mechanisms or resistance issues.

WO2024237519A1PCT designated stage expired Publication Date: 2024-11-21ABCLON
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005598
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-04-25
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Monotherapy with monoclonal antibodies (mAbs) is limited in treating cancers with complex mechanisms or those that develop resistance, necessitating a dual antigen targeting approach for enhanced therapeutic effects.

Method used

A dual antigen targeting protein complex is developed by combining an antibody or its antigen-binding fragment with an affibody, creating a protein structure that simultaneously recognizes and binds to two different antigens, specifically targeting Epidermal Growth Factor Receptor (EFGR) or Prostate-Specific Membrane Antigen (PSMA) and CD137, to enhance cancer treatment efficacy.

Benefits of technology

The dual antigen targeting protein complex demonstrates improved binding affinity and anticancer effects, increasing cytotoxicity and CD8 T cell activation, thereby providing a more effective treatment for various cancers compared to monotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005598_21112024_PF_FP_ABST
    Figure KR2024005598_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a dual antigen-targeting protein complex comprising an antibody or an antigen-binding fragment thereof and an affibody and, specifically, to a dual antigen-targeting protein complex comprising: an epidermal growth factor receptor (EGFR) or prostate specific membrane antigen (PSMA) target site comprising an antibody or an antigen-binding fragment thereof; and a CD137 target site comprising an affibody bound to the antibody or antigen-binding fragment thereof. When using the dual antigen-targeting protein complex or a composition comprising same, it is possible to effectively prevent or treat cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Dual antigen-targeting protein complex comprising an antibody or antigen-binding fragment thereof and an affibody

[0001] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0062007, filed with the Korean Intellectual Property Office on May 12, 2023, the disclosure of which is incorporated herein by reference.

[0002] The present invention relates to a dual antigen target protein complex comprising an antibody or an antigen-binding fragment thereof and an affibody.

[0003]

[0004] Monoclonal antibodies (mAbs) have proven to be useful tools for treating various cancer types. However, the increasing clinical use of mAbs has highlighted the limitations of monotherapy for cancer. This is especially true for cancers with complex mechanisms or those that rapidly develop resistance or tolerance following monotherapy.

[0005] Bispecific antibodies, or bispecific protein complexes, are artificial proteins capable of simultaneously binding to two different antigens or two different epitopes. These bispecific protein complexes have pioneered a wide range of applications, including redirection of T cells to tumor cells, dual targeting of different disease mediators, and targeted delivery of payloads. For example, the approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) marked important milestones in the research and development of bispecific antibodies.

[0006] In light of the limitations of the aforementioned monotherapy, synergistic therapeutic approaches utilizing two drugs targeting different targets are gaining attention. Dual-targeting drugs have been shown to exhibit greater therapeutic efficacy than single-targeting drugs, highlighting the urgent need for the development of structurally stable, dual-antigen-targeting protein complexes with superior anticancer properties.

[0007]

[0008] The present inventors have diligently researched and developed a dual antigen-targeting protein complex with superior anticancer effects. As a result, they discovered that combining antibodies or antigen-binding fragments thereof targeting each antigen with affibodies yields a dual antigen-targeting protein complex with superior binding affinity for each antigen and superior anticancer effects. This led to the completion of the present invention.

[0009] Accordingly, it is an object of the present invention to provide a dual antigen targeting protein complex comprising a first antigen targeting moiety comprising an antibody or an antigen-binding fragment thereof; and a second antigen targeting moiety comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0010] Another object of the present invention is to provide a nucleic acid molecule comprising a nucleotide sequence encoding the above dual antigen target protein complex.

[0011] Another object of the present invention is to provide a recombinant vector comprising the nucleic acid molecule.

[0012] Another object of the present invention is to provide a host cell comprising the recombinant vector.

[0013] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, comprising a dual antigen-targeting protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) targeting portion comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0014] Another object of the present invention is to provide a method for preventing or treating cancer, comprising a dual antigen-targeting protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) targeting moiety comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting moiety comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0015] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.

[0016]

[0017] In one aspect of the present invention, the present invention provides a dual antigen target protein complex comprising a first antigen target portion comprising an antibody or an antigen-binding fragment thereof; and a second antigen target portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0018] The present inventors have conducted extensive research to develop a dual antigen-targeting protein complex with superior anticancer effects. As a result, they have discovered that combining antibodies or antigen-binding fragments thereof targeting each antigen with affibodies can produce a dual antigen-targeting protein complex with superior binding affinity for each antigen and excellent anticancer effects.

[0019] The term "dual antigen-targeting protein complex" as used herein may be, but is not limited to, a bispecific antibody comprising two antibodies with different antigen-binding sites, a fusion protein comprising an antibody and an antigen-binding peptide, or a chimeric protein. Preferably, the dual antigen-targeting protein complex in the present invention refers to a form in which an antibody or an antigen-binding fragment thereof and an affibody are bound.

[0020] As used herein, the term “dual antigen targeting protein complex” refers to a protein structure capable of simultaneously recognizing and binding two different antigens.

[0021] According to one aspect of the present invention, the dual antigen-targeting protein complex is in the form of an antibody or antigen-binding fragment and an affibody linked together. The antibody or antigen-binding fragment and the affibody of the present invention are covalently linked to each other, and according to one embodiment of the present invention, the dual antigen-targeting protein complex can be implemented in the form of a fusion protein or a conjugate.

[0022] Thus, the antibody or antigen-binding fragment thereof and the affibody can be linked by chemical conjugation (known as organic chemistry methods) or other means (e.g., by expressing the complex as a fusion protein, directly or indirectly via a linker (e.g., an amino acid linker)).

[0023] According to a specific embodiment of the present invention, the antibody or antigen-binding fragment and the affibody forming the protein complex are connected by at least one linker. In this case, the linker may be composed of an amino acid sequence represented by the general formula (GnSm)p or (SmGn)p:

[0024] Here, n, m and p are independently,

[0025] n is an integer from 1 to 7;

[0026] m is an integer from 0 to 7;

[0027] The sum of n and m is an integer less than or equal to 8; and

[0028] p is an integer from 1 to 7.

[0029] According to another specific embodiment of the present invention, the linker is n = 1 to 5 and m = 0 to 5. In a more specific embodiment, n = 4 and m = 1.

[0030] In a more specific implementation, the linker is GGGGS.

[0031] As used herein, the term “antibody” includes complete antibody forms as well as antigen binding fragments of antibody molecules.

[0032] A complete antibody has a structure with two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond.

[0033] The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types and subclasses gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1), and alpha2 (α2). The light chain constant region has kappa and lambda types (Cellular and Molecular Immunology, Wonsiewicz, MJ, Ed., Chapter 45, pp. 41-50, WB Saunders Co. Philadelphia, PA (1991); Nisonoff, A., Introduction to Molecular Immunology, 2nd Ed., Chapter 4, pp. 45-65, Sinauer Associates, Inc., Sunderland, MA (1984)).

[0034] As used herein, the term "antigen-binding fragment" refers to a fragment having an antigen-binding function, and includes Fab, F(ab'), F(ab')2, chemically linked F(ab')2, and Fv. Among antibody fragments, Fab has one antigen-binding site in a structure having variable regions of the light and heavy chains, a constant region of the light chain, and the first constant region (CH1) of the heavy chain. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibodies are generated when cysteine ​​residues in the hinge region of Fab' form a disulfide bond. Fv is the minimum antibody fragment that has only the heavy chain variable region and the light chain variable region, and the recombinant technology for producing Fv fragments is disclosed in PCT International Patent Publication Nos. WO 88 / 10649, WO 88 / 106630, WO 88 / 07085, WO 88 / 07086, and WO 88 / 09344. A two-chain Fv has a heavy chain variable region and a light chain variable region linked by a non-covalent bond, and a single-chain Fv generally has a heavy chain variable region and a single chain variable region covalently linked by a peptide linker or directly linked at the C-terminus, so that they can form a dimer-like structure like a two-chain Fv. These antibody fragments can be obtained using proteolytic enzymes (for example, restriction digestion of whole antibodies with papain yields Fab fragments, and digestion with pepsin yields F(ab')2 fragments), or they can be produced using genetic recombination techniques.

[0035] In the present invention, the antibody is specifically in the form of scFv or a complete antibody. In addition, the heavy chain constant region may be selected from any one of the isotypes of gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε). The light chain constant region may be of the kappa or lambda type.

[0036] As used herein, the term "heavy chain" refers to both a full-length heavy chain and fragments thereof, comprising a variable region domain VH and three constant region domains CH1, CH2 and CH3, which comprise an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen. In addition, the term "light chain" as used herein refers to both a full-length light chain and fragments thereof, comprising a variable region domain VL and a constant region domain CL, which comprise an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen.

[0037] As used herein, the term "complementarity determining region (CDR)" refers to the amino acid sequence of the hypervariable region of the immunoglobulin heavy and light chains (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., US Department of Health and Human Services, National Institutes of Health (1987)). The heavy chain (CDR-H1, CDR-H2, and CDR-H3) and the light chain (CDR-L1, CDR-L2, and CDR-L3) each contain three CDRs. The CDRs provide the key contact residues for antibody binding to an antigen or epitope.

[0038] The antibody or antigen-binding fragment thereof as used herein includes full-length or intact polyclonal or monoclonal antibodies, as well as antigen-binding fragments thereof (e.g., Fab, Fab', F(ab')2, Fab3, Fv and variants thereof), fusion proteins comprising one or more antibody portions, human antibodies, humanized antibodies, chimeric antibodies, minibodies, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibodies (scFv), scFv-Fc, bispecific antibodies, multispecific antibodies, other modified arrangements of immunoglobulin molecules comprising an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies and covalently modified antibodies. Specific examples of modified antibodies and antigen-binding fragments thereof include nanobodies, AlbudAbs, DARTs (dual affinity re-targeting), BiTEs (bispecific T-cell engagers), TandAbs (tandem diabodies), DAFs (dual acting Fabs), two-in-one antibodies, SMIPs (small modular immunopharmaceuticals), FynomAbs (fynomers fused to antibodies), DVD-Igs (dual variable domain immunoglobulins), CovX-bodies (peptide modified antibodies), duobodies, and triomAbs. The list of such antibodies and antigen-binding fragments thereof is not limited to the above.

[0039] In this specification, the term "framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain is generally composed of four FR domains: FR1, FR2, FR3, and FR4.

[0040] Therefore, HVR and FR sequences generally appear in the following order in VH (or VL / Vk):

[0041] (a) FRH1 (Framework region 1 of Heavy chain)-CDRH1 (complementarity determining region 1 of Heavy chain)-FRH2-CDRH2-FRH3-CDRH3-FRH4; and

[0042] (b) FRL1 (Framework region 1 of Light chain)-CDRL1 (complementarity determining region 1 of Light chain)-FRL2-CDRL2-FRL3-CDRL3-FRL4.

[0043] As used herein, the term "variable region" or "variable domain" refers to a domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of native antibodies (VH and VL, respectively) generally have similar structures, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). (Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Additionally, antibodies that bind to a specific antigen can be isolated using the VH or VL domain from antibodies that bind to the antigen and screen a library of complementary VL or VH domains, respectively.

[0044] As used herein, the term "specifically binds" or the like means that an antibody or antigen-binding fragment thereof, or other construct such as a scFv, forms a complex with the antigen that is relatively stable under physiological conditions. Specific binding is at least about 1 x 10 -6 M or less (e.g. 9 x 10 -7 M, 8 x 10 -7 M, 7 x 10 -7 M, 6 x 10 -7 M, 5 x 10 -7 M, 4 x 10 -7 M, 3 x 10 -7 M, 2 x 10 -7 M, or 1 x 10 -7 M), preferably 1 x 10 -7 M or less (e.g. 9 x 10 -8 M, 8 x 10 -8 M, 7 x 10 -8 M, 6 x 10 -8 M, 5 x 10 -8 M, 4 x 10 -8 M, 3 x 10 -8 M, 2 x 10 -8 M, or 1 x 10 -8 M), more preferably 1 x 10 -8 M or less (e.g. 9 x 10 -9 M, 8 x 10 -9 M, 7 x 10 -9 M, 6 x 10 -9 M, 5 x 10 -9 M, 4 x 10 -9 M, 3 x 10 -9 M, 2 x 10 -9 M, or 1 x 10 -9 The equilibrium dissociation constant (KD) of the two molecules can be characterized by a KD of 1 (e.g., a smaller KD indicates a tighter binding). Methods for determining whether two molecules bind specifically are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, etc.

[0045] As used herein, the term "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule Y and its partner Y can generally be expressed in terms of the dissociation constant (Kd). Affinity can be measured by conventional methods known in the art, including those described herein.

[0046] Also, as used herein, the term "human antibody" refers to an antibody produced by a human or human cell, or an antibody derived from a non-human source utilizing human antibody repertoires or other human antibody coding sequences, which possesses an amino acid sequence corresponding to the amino acid sequence of that antibody. This definition of a human antibody excludes humanized antibodies that contain non-human antigen-binding residues.

[0047] As used herein, the term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, and the remainder of the heavy and / or light chain is derived from a different source or species.

[0048] The term "humanized antibody" as used herein refers to a chimeric immunoglobulin, immunoglobulin chain or fragment thereof (e.g., Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequence of an antibody) that contains minimal sequence derived from a non-human immunoglobulin (e.g., mouse) antibody. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some cases, residues from the Fv framework region (FR) of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized antibody may comprise residues that are not found in the recipient antibody or in the imported CDR or framework sequences. Such modifications are made to further improve and optimize antibody performance. Typically, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, wherein all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions have the sequence of an FR region of a human immunoglobulin. The humanized antibody will comprise at least a portion of an immunoglobulin constant region (Fc region) sequence, up to substantially a human immunoglobulin constant region (Fc region) sequence.

[0049] The variants are said to have "substantial similarity", meaning that the two peptide sequences share at least about 90% sequence identity, and more preferably at least about 95%, 98%, or 99% sequence identity, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights. Preferably, the non-identical residue positions differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functionality of the protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upward to compensate for the conservative nature of the substitutions.

[0050] These amino acid mutations are based on the relative similarity of the amino acid side-chain substituents, such as hydrophobicity, hydrophilicity, charge, and size. Analysis of the size, shape, and type of amino acid side-chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine are similar in size; and phenylalanine, tryptophan, and tyrosine are similar in shape. Therefore, based on these considerations, arginine, lysine, and histidine; alanine, glycine, and serine; and phenylalanine, tryptophan, and tyrosine can be considered biologically functional equivalents.

[0051] When introducing mutations, the hydrophobicity index (HID) of an amino acid can be considered. Each amino acid is assigned a HID based on its hydrophobicity and charge: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine ​​(+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[0052] The hydrophobic amino acid index is crucial for imparting interactive biological functions to proteins. It is well known that amino acids with similar hydrophobic indices must be substituted to retain similar biological activity. When introducing mutations based on hydrophobic indices, substitutions are preferably made between amino acids with a difference in hydrophobicity index of ±2, more preferably ±1, or even ±0.5.

[0053] Meanwhile, it is also well known that substitutions between amino acids having similar hydrophilicity values ​​result in proteins with equivalent biological activity. As disclosed in U.S. Patent No. 4,554,101, the following hydrophilicity values ​​are assigned to each amino acid residue: arginine (+3.0); lysine (+3.0); asphaltene (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine ​​(-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); Phenylalanine (-2.5); Tryptophan (-3.4). When introducing mutations with reference to hydrophilicity values, substitutions are preferably made between amino acids that exhibit a difference in hydrophilicity values ​​of within ± 2, more preferably within ± 1, and even more preferably within ± 0.5.

[0054] Amino acid exchanges in proteins that do not alter the overall activity of the molecule are well known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979). The most common exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly.

[0055] The antibody or antigen-binding fragment thereof of the present invention comprises an antibody or antigen-binding fragment thereof that contains minor changes to the amino acid sequence described above, i.e., modifications that have little effect on the tertiary structure and function of the antibody. Accordingly, in some embodiments, even if it does not match the sequence described above, it may have at least 100%, 93%, 95%, 96%, 97%, or 98% similarity.

[0056] In this specification, "affibody" is also expressed as "Z body" or "Zb." Affibody is a small protein composed of 58 amino acid residues. The 13 amino acids that form a bond with a target protein in the protein sequence of this affibody molecule can bind to various target antigens depending on the amino acid sequence, and can be arranged randomly, so that a library can be constructed. Similar to antibodies, affibody molecules that can bind to various target antigens can be selected from a library through screening methods such as phage display and yeast two hybrid (Y2H). In addition, affibodies have a very small molecular weight of 6.5 kDa, and compared to IgG type antibodies with a molecular weight of 150 kDa, they are characterized by systemic diffusion when administered to the human body and rapid filtration through renal filtration. Therefore, affibodies are mainly applied in the research and development of diagnostic samples (Goldstein R et al., 2013, Expert Rev Anticancer Ther.).

[0057] In one embodiment of the present invention, the dual antigen target protein complex is one in which an affibody dimer is bound to the C-terminus of the heavy chain of an antibody or an antigen-binding fragment thereof.

[0058] In one specific example of the present invention, the dual antigen target protein complex is one in which an affibody dimer is bound to the C-terminus of the heavy chain of an antibody or an antigen-binding fragment thereof:

[0059] The heavy chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 9, SEQ ID NO: 33, or SEQ ID NO: 57; and

[0060] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0061] In the present invention, a dimer can be formed by the combination of two affibody monomers having the same amino acid sequence. The dimer can be formed by hydrogen bonds, covalent bonds, and other intermolecular forces between each affibody unit. Preferably, each affibody constituting the affibody dimer is connected by at least one linker. In this case, the linker can be composed of an amino acid sequence represented by the general formula (GnSm)p or (SmGn)p:

[0062] Here, n, m and p are independently,

[0063] n is an integer from 1 to 7;

[0064] m is an integer from 0 to 7;

[0065] The sum of n and m is an integer less than or equal to 8; and

[0066] p is an integer from 1 to 7.

[0067] According to another specific embodiment of the present invention, the linker is n = 1 to 5 and m = 0 to 5. In a more specific embodiment, n = 4 and m = 1.

[0068] In a more specific implementation, the linker is GGGGS.

[0069] In one embodiment of the present invention, the dual antigen target protein complex has an affibody monomer bound to each of the C-terminals of the heavy chain and the light chain of an antibody or an antigen-binding fragment thereof.

[0070] In one specific example of the present invention, the dual antigen target protein complex has an affibody monomer bound to the C-terminus of each of the heavy chain and light chain of an antibody or an antigen-binding fragment thereof:

[0071] The heavy chain of the antibody or antigen-binding fragment thereof is composed of an amino acid sequence represented by SEQ ID NO: 9, SEQ ID NO: 33, or SEQ ID NO: 57;

[0072] The light chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 10, SEQ ID NO: 34, or SEQ ID NO: 58; and

[0073] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0074] In one embodiment of the present invention, an affibody dimer is bound to the C-terminus of the light chain of an antibody or an antigen-binding fragment thereof.

[0075] In one specific embodiment of the present invention, an affibody dimer is bound to the C-terminus of the light chain of an antibody or an antigen-binding fragment thereof:

[0076] The light chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 10, SEQ ID NO: 34, or SEQ ID NO: 58; and

[0077] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0078] In one embodiment of the present invention, the first antigen target site targets EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen); and the second antigen target site targets CD137.

[0079] As used herein, the term "Epidermal Growth Factor Receptor (EFGR)" refers to a receptor tyrosine kinase present on the surface of cells. EFGR is primarily involved in regulating important cellular processes such as cell growth, differentiation, and survival. When a ligand such as epidermal growth factor binds to EGFR, intracellular signaling pathways are activated, promoting cell division and growth. EGFR is frequently overexpressed or mutated in various types of cancer, particularly non-small cell lung cancer, colon cancer, and head and neck cancer, playing a crucial role in the growth and progression of cancer.

[0080] As used herein, the term "PSMA (Prostate-Specific Membrane Antigen)" refers to a membrane protein primarily expressed in prostate cells. PSMA expression tends to increase in prostate cancer, suggesting that it can be used as a target for prostate cancer diagnosis and treatment. PSMA also possesses enzymatic activity and may be involved in nutrient uptake and signal transduction in the extracellular environment.

[0081] As used herein, the term "CD137" refers to a co-stimulatory molecule expressed on the surface of T cells in the immune system. CD137 plays a crucial role in increasing T cell activation and survival. The binding of CD137 to its ligand promotes T cell activation and enhances the immune response. In cancer treatment, CD137 is being studied as a strategy to enhance T cell anti-tumor activity in combination with immune checkpoint inhibitors.

[0082] In one embodiment of the present invention, the affibody is composed of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.

[0083] An affibody comprising an amino acid sequence represented by sequence number 1 or sequence number 2 represents an affibody targeting CD137.

[0084] In one embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of the amino acid sequences represented by SEQ ID NO: 3 to SEQ ID NO: 8, comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of the amino acid sequences represented by SEQ ID NO: 27 to SEQ ID NO: 32, or comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of the amino acid sequences represented by SEQ ID NO: 51 to SEQ ID NO: 56.

[0085] In the present invention, SEQ ID NOs: 3 to 8 represent HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences of an antibody or antigen-binding fragment targeting EFGR, respectively. SEQ ID NOs: 27 to 32 represent HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences of an antibody or antigen-binding fragment targeting EFGR, respectively. SEQ ID NOs: 51 to 56 represent HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences of an antibody or antigen-binding fragment targeting PSMA, respectively.

[0086] In one embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain each consisting of the amino acid sequences represented by SEQ ID NO: 9 and SEQ ID NO: 10, a heavy chain and a light chain each consisting of the amino acid sequences represented by SEQ ID NO: 33 and SEQ ID NO: 34, or a heavy chain and a light chain each consisting of the amino acid sequences represented by SEQ ID NO: 57 and SEQ ID NO: 58. In the present invention, SEQ ID NO: 9 and SEQ ID NO: 10 represent the heavy chain and light chain sequences, respectively, of an antibody or antigen-binding fragment targeting EFGR. In the present invention, SEQ ID NO: 33 and SEQ ID NO: 34 represent the heavy chain and light chain sequences, respectively, of an antibody or antigen-binding fragment targeting EFGR. In the present invention, SEQ ID NO: 57 and SEQ ID NO: 58 represent the heavy chain and light chain sequences, respectively, of an antibody or antigen-binding fragment targeting PSMA.

[0087] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 11 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 12, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 19 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 20, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 35 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 36, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 43 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 44, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 59 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 60, or a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 67 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 68 In the present invention, the above SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 35, and SEQ ID NO: 43 refer to sequences in which an affibody monomer targeting CD137 is bound to the heavy chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above SEQ ID NO: 59 and SEQ ID NO: 67 refer to sequences in which an affibody monomer targeting CD137 is bound to the heavy chain of an antibody or antigen-binding fragment targeting PSMA.

[0088] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 13 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 14, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 21 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 22, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 37 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 38, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 45 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 46, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 61 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 62, or a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 69 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 70. In the present invention, the above SEQ ID NO: 13, SEQ ID NO: 21, SEQ ID NO: 37, and SEQ ID NO: 45 refer to sequences in which an affibody dimer targeting CD137 is bound to the heavy chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above SEQ ID NO: 61 and SEQ ID NO: 69 refer to sequences in which an affibody dimer targeting CD137 is bound to the heavy chain of an antibody or antigen-binding fragment targeting PSMA.

[0089] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 15 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 16 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 23 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 24 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 39 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 40 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 47 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 48 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 63 is bound and an affibody consisting of an amino acid sequence represented by SEQ ID NO. 64 A light chain comprising a monomer bound thereto, or a heavy chain comprising an affibody monomer having an amino acid sequence represented by SEQ ID NO: 71 bound thereto, and a light chain comprising an affibody monomer having an amino acid sequence represented by SEQ ID NO: 72 bound thereto. In the present invention, SEQ ID NO: 15, SEQ ID NO: 23, SEQ ID NO: 39, and SEQ ID NO: 47 refer to sequences in which an affibody monomer targeting CD137 is bound to a heavy chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, SEQ ID NO: 63, and SEQ ID NO: 71 refer to sequences in which an affibody monomer targeting CD137 is bound to a heavy chain of an antibody or antigen-binding fragment targeting PSMA.

[0090] In the present invention, the above sequence numbers 16, 24, 40, and 48 refer to sequences in which an affibody monomer targeting CD137 is bound to a light chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above sequence numbers 64 and 72 refer to sequences in which an affibody monomer targeting CD137 is bound to a light chain of an antibody or antigen-binding fragment targeting PSMA.

[0091] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 17 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 18, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 25 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 26, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 41 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 42, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 49 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 50, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 65 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 66, or a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 73 and an affibody consisting of an amino acid sequence represented by SEQ ID NO: 74 It includes a light chain to which a dimer is bound. In the present invention, the above SEQ ID NOs: 18, 26, 42, and 50 refer to sequences in which a CD137-targeting affibody dimer is bound to a light chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above SEQ ID NOs: 66 and 74 refer to sequences in which a CD137-targeting affibody dimer is bound to a light chain of an antibody or antigen-binding fragment targeting PSMA.

[0092]

[0093] In one aspect of the present invention, the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the dual antigen target protein complex.

[0094] In this specification, the term "nucleic acid molecule" has a meaning that comprehensively includes DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units in nucleic acid molecules, include not only natural nucleotides but also analogues in which the sugar or base portion is modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)).

[0095] It is sufficient for the nucleotide sequence encoding the antibody or antigen-binding fragment thereof of the present invention to be a nucleotide sequence encoding an amino acid sequence constituting the antibody or antigen-binding fragment thereof, and it is obvious to those skilled in the art that it is not limited to any specific nucleotide sequence.

[0096] This is because even if a mutation occurs in the nucleotide sequence, when the mutated nucleotide sequence is expressed as a protein, there are cases where it does not bring about a change in the protein sequence. This is called codon degeneracy. Therefore, the nucleotide sequence includes a nucleotide sequence that includes functionally equivalent codons, codons that encode the same amino acid (for example, due to codon degeneracy, there are six codons for arginine or serine), or codons that encode biologically equivalent amino acids.

[0097] Considering the mutations having the above-described biological equivalent activity, the nucleic acid molecule of the present invention encoding an amino acid sequence constituting the antibody or an antigen-binding fragment thereof is interpreted to also include a sequence showing substantial identity therewith. The above substantial identity means that when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art, at least 60% homology (e.g., 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, or 69%), more specifically 70% homology (e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, or 79%), even more specifically 80% homology (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%), and even more specifically 90% homology (e.g., 90% or more homology) By "homology" we mean sequences that exhibit a homology of at least 95% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%), most specifically, a homology of at least 95% (e.g., 95%, 96%, 97%, 98%, or 99%). All integers greater than or equal to 60% and less than or equal to 100%, and decimals therebetween, are encompassed within the scope of the present invention with respect to % homology.

[0098] Alignment methods for sequence comparison are well known in the art. Various alignment methods and algorithms are described in Smith and Waterman, Adv. Appl. Math. 2:482 (1981); Needleman and Wunsch, J. Mol. Bio. 48:443 (1970); Pearson and Lipman, Methods in Mol. Biol. 24: 307-31 (1988); Higgins and Sharp, Gene 73:237-44 (1988); Higgins and Sharp, CABIOS 5:151-3 (1989); Corpet et al., Nuc. Acids Res. 16:10881-90 (1988); Huang et al., Comp. Appl. BioSci. 8:155-65 (1992) and Pearson et al., Meth. Mol. Biol. 24:307-31 (1994). The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10 (1990)) is available from the National Center for Biological Information (NBCI) and can be used in conjunction with sequence analysis programs such as blastp, blastn, blastx, tblastn, and tblastx on the Internet. BLAST can be accessed through the BLAST page on the ncbi website. Instructions for comparing sequence homology using this program can be found on the BLAST help page on the ncbi website.

[0099] In one embodiment of the present invention, the nucleic acid molecule may comprise one or more of the amino acid sequences of SEQ ID NOs: 75 to 148.

[0100] The above sequence number 75 or sequence number 76 represents a nucleotide sequence encoding an affibody targeting CD137.

[0101] In the present invention, SEQ ID NOs: 77 to 82 represent nucleotide sequences encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of an antibody or antigen-binding fragment targeting EFGR, respectively. SEQ ID NOs: 101 to 106 represent nucleotide sequences encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of an antibody or antigen-binding fragment targeting EFGR, respectively. SEQ ID NOs: 125 to 130 represent nucleotide sequences encoding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of an antibody or antigen-binding fragment targeting PSMA, respectively.

[0102] In the present invention, SEQ ID NO: 83 and SEQ ID NO: 84 represent nucleotide sequences encoding the heavy chain and light chain of an antibody or antigen-binding fragment targeting EFGR, respectively. In the present invention, SEQ ID NO: 107 and SEQ ID NO: 108 represent nucleotide sequences encoding the heavy chain and light chain of an antibody or antigen-binding fragment targeting EFGR, respectively. In the present invention, SEQ ID NO: 131 and SEQ ID NO: 132 represent nucleotide sequences encoding the heavy chain and light chain of an antibody or antigen-binding fragment targeting PSMA, respectively.

[0103] In the present invention, the above SEQ ID NO: 85, SEQ ID NO: 93, SEQ ID NO: 109, and SEQ ID NO: 117 represent nucleotide sequences encoding a CD137-targeting affibody monomer bound to the heavy chain of an antibody or antigen-binding fragment targeting EFGR. The above SEQ ID NO: 86, SEQ ID NO: 94, SEQ ID NO: 110, and SEQ ID NO: 118 represent nucleotide sequences encoding a CD137-targeting affibody monomer bound to the heavy chain of an antibody or antigen-binding fragment targeting EFGR. The above SEQ ID NO: 133 and SEQ ID NO: 141 in the present invention represent nucleotide sequences encoding a CD137-targeting affibody monomer bound to the heavy chain of an antibody or antigen-binding fragment targeting PSMA. The above SEQ ID NO: 134 and SEQ ID NO: 142 represent nucleotide sequences encoding a PSMA-targeting affibody monomer's light chain.

[0104] In the present invention, SEQ ID NO: 87, SEQ ID NO: 95, SEQ ID NO: 111, and SEQ ID NO: 119 represent nucleotide sequences encoding a CD137-targeting affibody dimer bound to a heavy chain of an antibody or antigen-binding fragment targeting EFGR. SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 112, and SEQ ID NO: 120 represent nucleotide sequences encoding a CD137-targeting affibody dimer bound to a heavy chain of an antibody or antigen-binding fragment targeting EFGR. SEQ ID NO: 135 and SEQ ID NO: 143 in the present invention represent nucleotide sequences encoding a CD137-targeting affibody dimer bound to a heavy chain of an antibody or antigen-binding fragment targeting PSMA. SEQ ID NO: 136 and SEQ ID NO: 144 represent nucleotide sequences encoding a PSMA-targeting affibody dimer bound to a light chain of an antibody or antigen-binding fragment.

[0105] In the present invention, the above SEQ ID NO: 89, SEQ ID NO: 97, SEQ ID NO: 113, and SEQ ID NO: 121 refer to nucleotide sequences encoding a CD137-targeting affibody monomer bound to the heavy chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above SEQ ID NO: 137 and SEQ ID NO: 145 refer to nucleotide sequences encoding a CD137-targeting affibody monomer bound to the heavy chain of an antibody or antigen-binding fragment targeting PSMA.

[0106] In the present invention, the above SEQ ID NO: 90, SEQ ID NO: 98, SEQ ID NO: 114, and SEQ ID NO: 122 refer to nucleotide sequences encoding a CD137-targeting affibody monomer bound to the light chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, the above SEQ ID NO: 138 and SEQ ID NO: 146 refer to nucleotide sequences encoding a CD137-targeting affibody monomer bound to the light chain of an antibody or antigen-binding fragment targeting PSMA.

[0107] In the present invention, SEQ ID NO: 91, SEQ ID NO: 99, SEQ ID NO: 115, and SEQ ID NO: 123 refer to nucleotide sequences encoding the heavy chain of an antibody or antigen-binding fragment targeting EFGR. In the present invention, SEQ ID NO: 92, SEQ ID NO: 100, SEQ ID NO: 116, and SEQ ID NO: 124 refer to nucleotide sequences encoding the light chain of an antibody or antigen-binding fragment targeting EFGR, in which an affibody dimer targeting CD137 is bound. In the present invention, SEQ ID NO: 139 and SEQ ID NO: 147 refer to nucleotide sequences encoding the light chain of an antibody or antigen-binding fragment targeting PSMA. In the present invention, SEQ ID NO: 140 and SEQ ID NO: 148 refer to nucleotide sequences encoding the light chain of an antibody or antigen-binding fragment targeting PSMA, in which an affibody dimer targeting CD137 is bound.

[0108]

[0109] In one aspect of the present invention, the present invention provides a recombinant vector comprising the nucleic acid molecule.

[0110] The term "vector" as used herein refers to a means for expressing a target gene in a host cell, including but not limited to plasmid vectors; cosmid vectors; and viral vectors such as bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors.

[0111] According to one embodiment of the present invention, in the vector of the present invention, the nucleic acid molecule is operatively linked to a promoter.

[0112] As used herein, the term "operatively linked" refers to a functional association between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, whereby the regulatory sequence regulates transcription and / or translation of the other nucleic acid sequence.

[0113] The recombinant vector system of the present invention can be constructed through various methods known in the art, and specific methods thereof are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001), which is incorporated herein by reference.

[0114] The vector of the present invention can typically be constructed as a vector for cloning or as a vector for expression. In addition, the vector of the present invention can be constructed using a prokaryotic cell or a eukaryotic cell as a host.

[0115] For example, when the vector of the present invention is an expression vector and uses a eukaryotic cell as a host, a promoter derived from the genome of a mammalian cell (e.g., metallothionine promoter, beta-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of Moloney virus, promoter of Epstein-Barr virus (EBV), and promoter of Rous sarcoma virus (RSV)) can be used, and generally has a polyadenylation sequence as a transcription termination sequence.

[0116] The vector of the present invention may be fused with other sequences to facilitate purification of antibodies expressed therefrom. Examples of such fusion sequences include glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA), and 6x His (hexahistidine; Quiagen, USA).

[0117] Meanwhile, the expression vector of the present invention includes an antibiotic resistance gene commonly used in the art as a selectable marker, for example, a resistance gene for ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin, and tetracycline.

[0118] Optionally, the vector may additionally carry genes encoding reporter molecules (e.g., luciferase and -glucuronidase).

[0119] According to one embodiment of the present invention, the expression vector is a vector into which a nucleic acid molecule encoding a protein complex to which an antibody or an antigen-binding fragment thereof and an affibody are bound is inserted, and the vector is a recombinant vector for host cell expression that is operatively linked to a nucleotide sequence of the nucleic acid molecule and includes a promoter that forms an RNA molecule in a host cell and a poly A signal sequence that acts in the host cell to cause polyadenylation of the 3'-end of the RNA molecule.

[0120]

[0121] In one aspect of the present invention, the present invention provides a host cell comprising the recombinant vector.

[0122] Any host cell capable of stably and continuously cloning and expressing the vector of the present invention can be used, as is known in the art. For example, suitable eukaryotic host cells for the vector include, but are not limited to, yeast (Saccharomyce cerevisiae), insect cells, monkey kidney cells 7 (COS7), NSO cells, SP2 / 0, Chinese hamster ovary (CHO) cells, W138, baby hamster kidney (BHK) cells, MDCK, myeloma cell lines, HuT 78 cells, and HEK-293 cells.

[0123] As used herein, the terms "transformed," "transduced," or "transfected" refer to a process by which an exogenous nucleic acid is transferred or introduced into a host cell. A "transformed," "transduced," or "transfected" cell is a cell that has been transformed, transduced, or transfected with an exogenous nucleic acid, and the cell includes the cell and progeny cells resulting from passage thereof.

[0124] The method of delivering the vector of the present invention into a host cell, when the host cell is a eukaryotic cell, includes microinjection (Capecchi, MR, Cell, 22:479(1980)), calcium phosphate precipitation (Graham, FL et al., Virology, 52:456(1973)), electroporation (Neumann, E. et al., EMBO J., 1:841(1982)), liposome-mediated transfection (Wong, TK et al., Gene, 10:87(1980)), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5:1188-1190(1985)), and gene bombardment (Yang et al., Proc. Natl. Acad. Sci., 87:9568-9572(1990)). It can be injected into cells.

[0125] In the present invention, the recombinant vector injected into a host cell can express the recombinant protein complex described above within the host cell, and in such a case, a large amount of the protein complex is obtained. For example, if the expression vector includes the lac promoter, gene expression can be induced by treating the host cell with IPTG.

[0126] The above cultivation is typically performed under aerobic conditions, such as shaking culture or rotation using a rotator. The cultivation temperature is preferably in the range of 10 to 40°C, and the cultivation time is generally performed for 5 hours to 7 days. The pH of the medium is preferably maintained in the range of 3.0 to 9.0 during the cultivation. The pH of the medium can be adjusted with inorganic or organic acids, alkaline solutions, urea, calcium carbonate, ammonia, etc. During the cultivation, antibiotics such as ampicillin, streptomycin, chloramphenicol, kanamycin, and tetracycline can be added to maintain and express the recombinant vector, if necessary. When culturing a host cell transformed with a recombinant expression vector having an inducible promoter, an appropriate inducer can be added to the medium, if necessary. For example, if the expression vector contains a lac promoter, IPTG (isopropyl-beta-D-thiogalactopyranoside) can be added to the medium, and if it contains a trp promoter, indoleacrylic acid can be added to the medium.

[0127]

[0128] In one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a dual antigen-targeting protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) targeting portion comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0129] In one embodiment of the present invention, the cancer is selected from the group consisting of breast cancer, ovarian cancer, stomach cancer, lung cancer, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, head and neck cancer, skin cancer, thyroid cancer, parathyroid cancer, squamous cell carcinoma, peritoneal cancer, kidney cancer, testicular cancer, esophageal cancer, and ureteral cancer. However, the cancer is not limited thereto, and may be, for example, carcinoma, lymphoma, blastoma, sarcoma, neuroendocrine tumor, mesothelioma, schwannoma, meningioma, adenocarcinoma, or melanoma. However, the cancer is not limited thereto, and includes any cancer that overexpresses EGFR or PSMA on the surface of cancer cells.

[0130] Since the pharmaceutical composition of the present invention uses a protein complex comprising the antibody of the present invention or an antigen-binding fragment thereof and an affibody as an active ingredient, description of common contents between the two is omitted to avoid excessive complexity of the present specification.

[0131] In one embodiment of the present invention, the cancer is selected from the group consisting of breast cancer, ovarian cancer, stomach cancer, lung cancer, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, colon cancer, rectal cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, head and neck cancer, skin cancer, thyroid cancer, parathyroid cancer, squamous cell carcinoma, peritoneal cancer, kidney cancer, testicular cancer, esophageal cancer, and ureteral cancer. However, the cancer is not limited thereto, and may be, for example, carcinoma, lymphoma, blastoma, sarcoma, neuroendocrine tumor, mesothelioma, schwannoma, meningioma, adenocarcinoma, or melanoma. However, the cancer is not limited thereto, and includes any cancer that overexpresses EGFR or PSMA on the surface of cancer cells.

[0132] Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents, preservatives, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0133] The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered by, for example, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intrasternal injection, topical administration, intranasal administration, intrapulmonary administration, and rectal administration.

[0134] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg. The term "pharmaceutically effective amount" as used herein means an amount sufficient to prevent or treat the above-mentioned disease.

[0135] As used herein, the term "prevention" means the prevention or protective treatment of a disease or disease state. As used herein, the term "treatment" means the reduction, suppression, alleviation or eradication of a disease state.

[0136] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by placing it in a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains, and the like. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, suppository, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.

[0137] In one embodiment of the present invention, the dual antigen target protein complex is one in which an affibody dimer is bound to the C-terminus of the heavy chain of an antibody or an antigen-binding fragment thereof.

[0138] In one specific example of the present invention, the dual antigen target protein complex is one in which an affibody dimer is bound to the C-terminus of the heavy chain of an antibody or an antigen-binding fragment thereof:

[0139] The heavy chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 9, SEQ ID NO: 33, or SEQ ID NO: 57; and

[0140] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0141] In one embodiment of the present invention, the dual antigen target protein complex has an affibody monomer bound to each of the C-terminals of the heavy chain and the light chain of an antibody or an antigen-binding fragment thereof.

[0142] In one specific example of the present invention, the dual antigen target protein complex has an affibody monomer bound to the C-terminus of each of the heavy chain and light chain of an antibody or an antigen-binding fragment thereof:

[0143] The heavy chain of the antibody or antigen-binding fragment thereof is composed of an amino acid sequence represented by SEQ ID NO: 9, SEQ ID NO: 33, or SEQ ID NO: 57;

[0144] The light chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 10, SEQ ID NO: 34, or SEQ ID NO: 58; and

[0145] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0146] In one embodiment of the present invention, the dual antigen target protein complex is one in which an affibody dimer is bound to the C-terminus of the light chain of an antibody or an antigen-binding fragment thereof.

[0147] In one specific embodiment of the present invention, an affibody dimer is bound to the C-terminus of the light chain of an antibody or an antigen-binding fragment thereof:

[0148] The light chain of the antibody or antigen-binding fragment thereof consists of an amino acid sequence represented by SEQ ID NO: 10, SEQ ID NO: 34, or SEQ ID NO: 58; and

[0149] The above-mentioned affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

[0150] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 11 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 12, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 19 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 20, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 35 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 36, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 43 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 44, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 59 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 60, or a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 67 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 68 It contains light chains.

[0151] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 13 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 14, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 21 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 22, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 37 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 38, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 45 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 46, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 61 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 62, or a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 69 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 70. It contains light chains.

[0152] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 15 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 16 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 23 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 24 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 39 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 40 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 47 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 48 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 63 is bound and an affibody consisting of an amino acid sequence represented by SEQ ID NO. 64 A light chain comprising a monomer bound thereto, or a heavy chain comprising an affibody monomer bound thereto, comprising an amino acid sequence represented by SEQ ID NO: 71, and a light chain comprising an affibody monomer bound thereto, comprising an amino acid sequence represented by SEQ ID NO: 72.

[0153] In one embodiment of the present invention, the dual antigen target protein complex comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 17 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 18, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 25 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 26, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 41 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 42, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 49 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 50, a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 65 and a light chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 66, or a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 73 and an affibody consisting of an amino acid sequence represented by SEQ ID NO: 74 It contains a light chain with a dimer attached.

[0154]

[0155] In one aspect of the present invention, a method for preventing or treating cancer is provided, comprising administering to a subject a dual antigen-target protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) target region comprising an antibody or an antigen-binding fragment thereof; and a CD137 target region comprising an affibody bound to the antibody or an antigen-binding fragment thereof, or a pharmaceutical composition comprising the same.

[0156] Since the method for preventing or treating cancer of the present invention administers a dual antigen target protein complex or a pharmaceutical composition containing the same to a subject, common contents related to the dual antigen target protein complex or a pharmaceutical composition containing the same are omitted to avoid excessive complexity of the present specification.

[0157]

[0158] The features and advantages of the present invention are summarized as follows:

[0159] (a) The present invention provides a dual antigen target protein complex comprising a first antigen targeting portion comprising an antibody or an antigen-binding fragment thereof; and a second antigen targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0160] (b) The present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the above dual antigen target protein complex.

[0161] (c) The present invention provides a recombinant vector comprising the nucleic acid molecule.

[0162] (d) The present invention provides a host cell comprising the recombinant vector.

[0163] (e) The present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a dual antigen-targeting protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) targeting portion comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

[0164] (f) The present invention provides a method for preventing or treating cancer, comprising administering to a subject a dual antigen-targeting protein complex comprising an Epidermal Growth Factor Receptor (EFGR) or Prostate-Specific Membrane Antigen (PSMA) targeting portion comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof, or a pharmaceutical composition comprising the same.

[0165] (g) When the dual antigen target protein complex of the present invention or a composition containing the same is used, cancer can be effectively prevented or treated.

[0166]

[0167] Figure 1 schematically illustrates the optimized form of a dual antigen target protein complex.

[0168] Figure 2 shows the results of producing various forms of dual antigen target protein complexes based on cetuximab using animal cells and confirming successful production through SDS-PAGE.

[0169] Figure 3a shows the results of comparing the binding affinity of CET_ZAAD01D and CET_ZAAD01M4 to CD137 and EGFR proteins.

[0170] Figure 3b shows the results comparing the binding affinity of CET_ZAAD05D and CET_ZAAD05M4 to CD137 and EGFR proteins.

[0171] Figure 3c shows the results of comparing the binding affinity of CET_ZAAD01D and CET_ZAAD01D_LC to CD137 and EGFR proteins.

[0172] Figure 3d shows the results of comparing the binding affinity of CET_ZAAD05D and CET_ZAAD05D_LC to CD137 and EGFR proteins.

[0173] Figure 4 shows the results comparing the binding affinity of various forms of dual antigen targeting protein complexes based on cetuximab to activated CEMT cells expressing CD137.

[0174] Figure 5a shows the results of a comparison of anticancer effects through cytotoxicity tests of various forms of dual antigen target protein complexes CET_ZAAD01D, CET_ZAAD01M4, CET_ZAAD05D, and CET_ZAAD05M4 based on cetuximab.

[0175] Figure 5b shows the results of a comparison of anticancer effects through cytotoxicity tests of various forms of dual antigen target protein complexes CET_ZAAD01D, CET_ZAAD0d_LC, ZAAD05D, and CET_ZAAD05D_LC based on cetuximab.

[0176] Figures 6a and 6b show the results of comparing the activation ability of EGFR protein-dependent CD8 T cells of various forms of dual antigen targeting protein complexes based on cetuximab.

[0177] Figure 7 shows the results of a comparison of the HT29 cell-dependent CD8 T cell activation abilities of various forms of dual antigen targeting protein complexes based on cetuximab.

[0178] Figures 8a, 8b, 8c and 8d show the results of comparing the purity of various forms of dual antigen target protein complexes based on cetuximab using SEC-HPLC.

[0179] Figure 9 shows the results of cytotoxicity tests to confirm the anticancer effects of various forms of dual antigen target protein complexes based on 15E3.

[0180] Figure 10 shows the results of producing a dual antigen target protein complex based on an antibody targeting PSMA and confirming it by SDS-PAGE.

[0181] Figure 11 shows the results of analyzing the LNCap cell-dependent CD8 T cell activation ability of a dual antigen targeting protein complex based on an antibody targeting PSMA.

[0182]

[0183] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.

[0184]

[0185] Example

[0186] Example 1: Preparation of various types of dual antigen-targeting protein complexes.

[0187] To create a protein complex targeting a dual antigen, antibodies and affibodies were combined to create a protein complex. To determine the optimal form of the protein complex, a form similar to that shown in Figure 1 was obtained through genetic cloning. Protein complexes of this form were produced using animal cells, and their size and purity were confirmed using SDS-PAGE.

[0188] 1 x 10 HEK293F cells 6100 mL was prepared at a concentration of cells / mL and cultured with shaking at 37°C, 8% CO2, and 125 RPM. 5 mL of culture medium was added to a sterile 15 mL tube, and the expression vector DNA expressing the heavy and light chain DNA of the antibody was added and mixed to prepare DNA. PEI (Polysciences, cat. #. 23966) was added to the 15 mL tube containing the culture medium and DNA, mixed, and then added to HEK293F cells and cultured for 7 days. The recombinant protein in the culture medium was purified using Protein A resin (GE healthcare, cat. #. 17-5438-03) and the buffer was replaced using the diafiltration method (Satorius, cat. #. VS2002). The purified recombinant protein was quantified by measuring the absorbance at a wavelength of 280 nm. The purified recombinant protein was analyzed on a 4-20% gradient SDS-PAGE.

[0189] Based on the basic form in which an Affibody is bound to the C-terminus of the antibody heavy chain, various optimized forms of dual antigen-targeting protein complexes were fabricated. The form in which an Affibody dimer is added to the C-terminus of the antibody heavy chain is referred to as the D form, the form in which an Affibody is added to both the C-termini of the antibody heavy chain and the C-termini of the light chain is referred to as the M4 form, and the form in which an Affibody dimer is added to the C-terminus of the antibody light chain is referred to as the D_LC form. The structures of the fabricated dual antigen-targeting protein complexes are shown in Figure 1.

[0190]

[0191] Example 2: Production of various types of dual antigen-targeting protein complexes based on an antibody (cetuximab) targeting EFGR.

[0192] The dual antigen target protein complex of the form conceived above was produced using Cetuximab antibody and affibody (ZAAD01 / ZAAD05) that binds to CD137. The names of the dual antigen target complex proteins of D form, M4 form, and D_LC form produced using Cetuximab and affibody were designated as CET_ZAAD01D / CET_ZAAD05D, CET_ZAAD01M4 / CET_ZAAD05M4, and CET_ZAAD01D_LC / CET_ZAAD05D_LC, respectively.

[0193] The SDS-PAGE results confirmed whether each bispecific antibody was successfully produced in the intended size.

[0194] The results are shown in Fig. 2.

[0195] As shown in Fig. 2, compared to CET, heavy chain bands with increased molecular weight were observed in CET_ZAAD01 and CET_ZAAD05, and compared to CET_ZAAD01 and CET_ZAAD05, heavy chain bands with increased molecular weight were observed in CET_ZAAD01D and CET_ZAAD05D. Compared to CET, light chain and heavy chain bands with increased molecular weight were observed in CET_ZAAD01M4 and CET_ZAAD05M4. Compared to CET_ZAAD01D and CET_ZAAD05D, heavy chain bands with decreased molecular weight and light chain bands with increased molecular weight were observed in CET_ZAAD01D_LC and CET_ZAAD05D_LC. Therefore, it was confirmed that each type of bispecific antibody was successfully produced (reducing conditions in Fig. 2). Some of the optimized bispecific antibody candidates (CET_ZAAD01D / CET_ZAAD05D / CET_ZAAD05_LC) exhibited larger-than-normal bands (non-reducing conditions in Figure 2).

[0196]

[0197] Example 3: Comparison of target binding abilities of antigen-target protein complexes based on antibodies (cetuximab) targeting EFGR.

[0198] The binding affinity of the purified dual antigen-target protein complex to the target protein or cells expressing it was analyzed. Using eight types of produced dual antigen-target protein complexes, the binding of CD137 and EGFR proteins was confirmed using ELISA. For ELISA, eight types of purified dual antibodies were diluted 1 / 5 from 60 nM and treated in 7 points on each plate coated with hCD137-ECD-Fc and hEGFR-ECD-Fc proteins at a concentration of 1 ug / mL, and after treatment with a secondary antibody (anti-hIgG-Fab-HRP (Jackson, JAC-109-035-097)), a colorimetric reaction was induced with TMB (biofx, TMBC-1000-01). The OD450 value was measured using an ELISA reader (Victor X3 Perkinelmer) and the EC50 value was obtained through Graph Prism.

[0199] The results are shown in Fig. 3a, Fig. 3b, Fig. 3c, Fig. 4d, Table 1 and Table 2.

[0200] As shown in Fig. 3a, it was confirmed that there was no difference in the binding degree of CET_ZAAD01, CET_ZAAD01D, and CET_ZAAD01M4 to CD137 protein. As shown in Table 1, there was also no difference in the actual EC50 value. As shown in Fig. 3b, the binding degree of CET_ZAAD05D and CET_ZAAD05M4 to CD137 protein was increased compared to CET_ZAAD05, and as shown in Table 1, the actual EC50 value was also confirmed to be improved by more than ten times.

[0201] Analysis of binding affinity of CET_ZAAD01D, CET_ZAAD01M4, CET_ZAAD05D, and CET_ZAAD05M4 to CD137 and EGFR proteins. EC50CD137EGFRCET_ZAAD010.0550.073CET_ZAAD01D0.0470.100CET_ZAAD01M40.0460.121CET_ZAAD051.1940.087CET_ZAAD05D0.1280.086CET_ZAAD05M40.0920.155

[0202]

[0203] As shown in Fig. 3c, Fig. 3d, and Table 2, for CET_ZAAD01D_LC and CDT_ZAAD05D_LC, it was confirmed graphically that the degree of binding was reduced or similar to that of CET_ZAAD01 and CET_ZAAD05.

[0204] Analysis of binding affinity of CET_ZAAD01D, CET_ZAAD01_LC, CET_ZAAD05D, and CET_ZAAD05_LC to CD137 and EGFR proteins. EC50CD137EGFRCET_ZAAD010.0990.110CET_ZAAD01D0.0740.147CET_ZAAD01D_LC0.2580.236CET_ZAAD052.2310.263CET_ZAAD05D0.1690.114CET_ZAAD05D_LC0.8670.150

[0205]

[0206] To determine the binding ability of various forms of dual antigen targeting protein complexes to CD137-expressing cells, CEMT cells (ATCC, CCL-119) were cultured at 1 X 10 7 / 10 mL was prepared, treated with 50 ng / mL of PMA (Sigma, P1585) and 1 ug / mL of ionomycin (Sigma, I9657), and then cultured for 16 hours to activate. Activated CEMT cells (ATCC, CCL-119) were cultured at 5X10 5 / tube concentration was prepared and the cells were collected by centrifugation at 1200 rpm for 3 minutes, washed with PBS containing 5% FBS. Afterwards, the dual antigen-target protein complex was treated at 0.48 nM and incubated on ice for 1 hour. Afterwards, the cells were washed three times with 200 uL of PBS containing 5% FBS by centrifugation at 1200 rpm for 3 minutes. Then, the cells were treated with anti-human-Fc-FITC (LT, A11013) at 1 ug / mL and incubated on ice for 45 minutes while protected from light. The cells were washed three times with 200 uL of 5% FBS in PBS by centrifugation at 1200 rpm for 3 minutes, and the fluorescence intensity was measured using a Beckman Coulter FACS instrument.

[0207] The results are shown in Fig. 4.

[0208] As shown in Fig. 4, when the degree of binding to activated CEMT cells was confirmed, CET_ZAAD01D had a similar MFI value compared to CET_ZAAD01, CET_ZAAD01M4 had an increased MFI value, and CET_ZAAD01D_LC had a decreased MFI value. CET_ZAAD05D had a similar MFI value compared to CET_ZAAD05, CET_ZAAD01M4 had an increased MFI value, and CET_ZAAD05D_LC had a similar MFI value.

[0209]

[0210] Example 4: Comparison of cytotoxicity of dual antigen targeting protein complexes based on an antibody (cetuximab) targeting EFGR.

[0211] Using the produced dual antigen target protein complex, the possibility of anticancer effect was confirmed by comparing the degree of cytotoxicity under co-culture conditions of PBMC and EGFR-expressing cells. 50 uL of anti-CD3 antibody (Invitrogen, 16-0037-85) was coated on a 96-well round plate at a concentration of 5 ug / mL one day before. Three washes were performed using 100 uL of culture medium (RPMI1640, 10% FBS), and 100 uL of culture medium (RPMI1640, 10% FBS) was treated to perform blocking for 1 hour at 37℃. The culture medium (RPMI1640, 10% FBS) in the plate was removed cleanly, and 1.0 X 10 DLD-1 expressing luciferase was added to the culture medium. 5 / mL concentration. Afterwards, 50 μL was treated with 8 kinds of dual antigen target protein complexes diluted 1 / 10 from 1 nM and 50 μL was treated at 6 points. In the meantime, blood donated from a healthy donor was diluted 1 / 2 with PBS, placed in a Leucosep tube (greiner bio-one, 227290) floating Picoll (GE healthcare, 17-1440-12), and centrifuged at 1000 g for 30 minutes. Only the layer of PBMCs located on the Picoll (GE healthcare, 17-1440-12) was recovered. After repeating the washing process of PBMCs with 2% in PBS and centrifuging at 300 g for 10 minutes twice, the number of PBMCs was measured. 1.0 X 10 5 / mL concentration and cultured for 3 days. The 96-well plate cultured for 3 days was centrifuged at 2000 RPM for 2 minutes to perform cell down. 50 μl / well of the culture was transferred to a 96-well V-bottom plate and stored for future experiments. 50 μl / well of 3X lysis buffer (75 mM Tris (pH 8.0), 30% glycerol, 3% Triton X-100) was dispensed into the remaining 96-well round plate and mixed well. Incubated at room temperature for 15 minutes. After the reaction, 50 μl / well of the sample was dispensed into a 96-well white plate, and 50 μl / well of the luciferase assay reagent (Promega, G7940) was dispensed and mixed well. The reaction was carried out at room temperature for 15 minutes, protected from light. After the reaction was completed, measurements were taken using VITORTM X3 equipment.

[0212] The results are shown in Figures 5a and 5b.

[0213] As shown in Fig. 5a and Fig. 5b, the cytotoxicity test results confirmed that the cytotoxicity of the protein complexes of the D form, M4 form, and D_LC form increased compared to the basic form of the dual antigen target protein complex. Compared to CET_ZAAD01, the cytotoxicity of CET_ZAAD01D and CET_ZAAD01M4 increased, and the cell death rate was confirmed to improve from about 50% at the maximum value to about 70%. Compared to CET_ZAAD05, CET_ZAAD05D and CET_ZAAD05M4 were confirmed to improve the cell death rate from about 40% at the maximum value to about 65%. CET_ZAAD01D_LC showed cytotoxicity efficacy similar to that of CET_ZAAD01D, and CET_ZAAD05D_LC also showed cytotoxicity efficacy similar to that of CET_ZAAD05D.

[0214]

[0215] Example 5: Comparison of CD8 T cell activation abilities of various forms of dual antigen targeting protein complexes based on an antibody (cetuximab) targeting EFGR.

[0216] Using the various forms of dual antigen target protein complexes produced, the ability of CD8 T cells to activate EGFR-dependently was compared. 50 μL of anti-CD3 antibody (Invitrogen, 16-0037-85) was coated onto 96-well round plates one day in advance at a concentration of 3 μg / mL. The following day, three washes were performed using 100 μL of sterile PBS. 50 μL of hEGFR-ECD-Fc was again coated onto the plates at a concentration of 5 μg / mL and incubated at 37°C for 3 hours. Three washes were performed using 100 μL of R10 media (RPMI 1640, 10% FBS, 10 mM Hepes), and 100 μL of R10 media (RPMI 1640, 10% FBS, 10 mM Hepes) was added, followed by blocking at 37°C for 1 hour. The R10 medium (RPMI1640, 10% FBS, 10 mM Hepes) on the plate was removed cleanly, and six types of dual antibodies were diluted 1 / 5 from 5 nM and treated with 50 μL of 4 points for 30 minutes. Meanwhile, blood donated from a healthy donor was diluted 1 / 2 with PBS, placed in a Leucosep tube (greiner bio-one, 227290) floating on Picoll (GE healthcare, 17-1440-12), and centrifuged at 1000 g for 30 minutes. Only the layer of PBMCs on top of Picoll (GE healthcare, 17-1440-12) was recovered. After washing the PBMCs twice with 2% in PBS and centrifuging them at 300 g for 10 minutes, the number of PBMCs was measured. CD8 positive T cells were prepared by the process of CD8 isolation kit (Myltenybiotec / 130-096-495) from PBMC. The number of CD8+ T cells was measured and 1.4 X 10 6After dissolving in R10 medium (RPMI1640, 10% FBS, 10 mM Hepes) to / mL, 50 uL was treated on the plate treated with the dual antigen-target protein complex. After 3 days of treatment, the plate was centrifuged at 2000 RPM for 10 minutes, and the supernatant was collected, and the process of the IFN-γ measurement kit (BD, 555142) was performed using this. The degree of CD8 T cell activity was compared through the measurement of CD8 T cell proliferation (WST-8) and IFN-γ.

[0217] The results are shown in Figures 6a and 6b.

[0218] As shown in Figures 6a and 6b, the activation ability of CD8 T cells was superior in the D and M4 forms than in the basic form of the dual antigen target protein complex. As shown in Figure 6a, the proliferation of CD8 T cells increased in CET_ZAAD01D and CET_ZAAD01M4 compared to CET_ZAAD01, and increased in CET_ZAAD05D and CET_ZAAD05M4 compared to CET_ZAAD05. As shown in Figure 6b, secreted IFN-γ also showed similar results to cell proliferation.

[0219]

[0220] Additionally, a CD8 T cell activation test was performed using HT29, an EGFR-expressing cell, for comparison.

[0221] One day before, 50 μL of anti-CD3 antibody (Invitrogen, 16-0037-85) was coated on a 96-well round plate at a concentration of 3 μg / mL. The next day, three washes were performed using 100 μL of sterile PBS. Three washes were performed using 100 μL of R10 media (RPMI1640, 10% FBS, 10 mM Hepes), and 100 μL of R10 media (RPMI1640, 10% FBS, 10 mM Hepes) was treated and blocking was performed for 1 hour at 37°C. The R10 media (RPMI1640, 10% FBS, 10 mM Hepes) in the plate was removed cleanly, and the number of HT29 cells was measured to be 7 X10 5 After dissolving in R10 medium to reach 100 nM / mL, 50 μL was treated on the plate. Six types of dual antigen target protein complexes were diluted 1 / 5 from 5 nM and treated with 50 μL in 4 points for 30 minutes. Meanwhile, blood donated from a healthy donor was diluted 1 / 2 with PBS, placed in a Leucosep tube (greiner bio-one, 227290) suspended in Picoll (GE healthcare, 17-1440-12), and centrifuged at 1000 g for 30 minutes. Only the layer of PBMCs on top of Picoll (GE healthcare, 17-1440-12) was recovered. After repeating the washing process of centrifuging at 300 g for 10 minutes twice using PBS containing 2% PBMC, the number of PBMCs was measured. PBMCs were prepared as CD8-positive T cells using the CD8 isolation kit (Myltenybiotec / 130-096-495). The number of CD8+ T cells was measured and 1.4 X 10 6After dissolving in R10 medium (RPMI1640, 10% FBS, 10 mM Hepes) to / mL, 50 uL was treated on the plate treated with the dual antigen-target protein complex. After 3 days of treatment, the plate was centrifuged at 2000 RPM for 10 minutes, and the supernatant was collected, and the process of the IFN-γ measurement kit (BD, 555142) was performed using this. The activity level of CD8 T cells was compared by measuring the amount of IFN-γ expression.

[0222] The results are shown in Fig. 7.

[0223] As shown in Fig. 7, it was confirmed that the amount of secreted IFN-γ of CET_ZAAD01D and CET_ZAAD01M4 was significantly increased compared to CET_ZAAD01, and it was also confirmed that the amount of secreted IFN-γ of CET_ZAAD05D and CET_ZAAD05M4 was significantly increased compared to CET_ZAAD05.

[0224]

[0225] Example 6: SEC-HPLC analysis of various forms of dual antigen-targeting protein complexes based on an antibody (cetuximab) targeting EFGR.

[0226] The purity of the produced dual antigen target protein complexes was compared through SEC-HPLC analysis. To confirm the purity, the dual antigen target protein complexes were prepared at a concentration of 1 mg / mL and filtered through a 0.2 μm PES filter. The filtered dual antigen target protein complexes were dispensed into 20 μL screw vials for HPLC analysis. The mobile phase buffer (0.1 M sodium phosphate + 0.2 M arginine, pH 6.8) was connected to the HPLC instrument, and the SEC_HPLC (TOSOH, SWXL3000 -7.8 mm x 30 cm) column used for the analysis was also connected. The following settings were set in the METHOD: flow rate 0.8 mL / min, detection 280 nm, injection volume 10 μL, and temperature 25°C. The analysis order and sample names were entered into the instrument's program according to the number of samples to be analyzed, and the instrument was started to analyze each dual antigen target protein complex. The detection time and peak area of ​​each sample were analyzed using an HPLC analysis program.

[0227] The results are shown in Fig. 8a, Fig. 8b, Fig. 8c, Fig. 8d and Table 3.

[0228] As shown in Fig. 8a, Fig. 8b, Fig. 8c, Fig. 8d and Table 3, purity analysis was performed on six types of optimized double antibodies by SEC_HPLC. The time of the main peak was confirmed in comparison with CET, and the purity of each was analyzed accordingly. As shown in Fig. 8a, Fig. 8b, Fig. 8c, Fig. 8d and Table 3, CET_ZAAD01 was confirmed to have a purity of 98%, CET_ZAAD01D was confirmed to have a purity of about 83%, and CET_ZAAD01M4 was confirmed to have a purity of about 97%. CET_ZAAD05 was confirmed to have a purity of about 97%, CET_ZAAD05D was confirmed to have a purity of about 64%, and CET_ZAAD05M4 was confirmed to have a purity of about 89%.

[0229]

[0230] SEC-HPLC main peak purityMain PeakRetention time (min)Area percentage (%)CET10.3399.41CET_ZAAD019.8498.03CET_ZAAD01D9.5882.50CET_ZAAD01M49 .6597.42CET_ZAAD059.8397.58CET_ZAAD05D9.5363.99CET_ZAAD05M49.6488.83

[0231]

[0232] The comprehensive evaluation results of various types of dual antigen target protein complexes based on cetuximab are shown in Table 4.

[0233]

[0234] Comprehensive evaluation results of cetuximab-based dual antigen targeting protein complex Protein binding Cell binding Cytotoxicity CD8 T cell activation EC50 (nM) MFI Maxinal activity (%) Maxinal activity (OD, pg / mL, pg / mL) 1st2nd 1st2nd 1st2nd Proliferation IFN-Gamma IFN-Gamma CD137 EGFR CD137 EGFR Activated CEMT DLD-1 EFGR protein dependent HT29 cell dependentCET_ZAAD010.060.070.100.1137.3024.9048.49N / A0.812031.4736649.50CET_ZAAD01D0.050.100.070.1534.6026.2067.6646.600. 983580.71101752.55CET_ZAAD01M40.050.12N / A51.90N / A69.3646.101 .032784.59115571.80CET_ZAAD01D_LCN / A0.260.24N / A16.70N / A38.80N / AN / AN / ACET_ZAAD051.190.092.230.269.057.6640.33N / A0.571195.9017418.36CET_ZAAD05D0.130.090.170.1112.109.5565.7038.400.763809.2594241.90CET_ZAAD05M40.090.16N / A30.60N / A63.4741.700.652032.2198540.29CET_ZAAD05D_LCN / A0.870.15N / A7.42N / A32.70N / AN / AN / A

[0235]

[0236] Example 7: Comparison of cytotoxicity of various forms of dual antigen targeting protein complexes based on an antibody (15E3) targeting EFGR.

[0237] A dual antigen target protein complex based on the EGFR-specific antibody 15E3 was produced using the same method as in Example 1, and the possibility of anticancer effects was confirmed by comparing the degree of cytotoxicity under co-culture conditions of PBMC and EGFR-expressing cells. 50 μL of anti-CD3 antibody (Invitrogen, 16-0037-85) was coated on a 96-well round plate at a concentration of 5 μg / mL one day before. 100 μL of culture medium (RPMI1640, 10% FBS) was used to wash the plate three times, and 100 μL of culture medium (RPMI1640, 10% FBS) was added to block the plate at 37°C for 1 hour. The culture medium (RPMI1640, 10% FBS) on the plate was removed cleanly, and 1.0 X 10 DLD-1 expressing luciferase was added to the culture medium. 5 After dissolving / mL, 50 μL was treated on the plate. Afterwards, 8 kinds of dual antibodies were diluted 1 / 10 from 1 nM and treated 6 points with 50 μL. Meanwhile, blood donated from a healthy donor was diluted 1 / 2 with PBS, placed in a Lucosep tube (greiner bio-one, 227290) floating Picoll (GE healthcare, 17-1440-12), and centrifuged at 1000 g for 30 minutes. Only the layer of PBMCs located on the Picoll (GE healthcare, 17-1440-12) was recovered. After repeating the washing process of centrifuging PBMCs twice with 2% in PBS at 300 g for 10 minutes, the number of PBMCs was measured. 1.0 X 10 5After dissolving / mL, 50 uL was treated on the plate and cultured for 3 days. The 96-well plate cultured for 3 days was centrifuged at 2000 RPM for 2 minutes to perform cell down. The culture medium was transferred to a 96-well V-bottom plate at 50 μl / well and stored for later experiments. 50 μl / well of 3X Lysis Buffer (75 mM Tris (pH 8.0), 30% glycerol, 3% Triton X-100) was dispensed into the remaining 96-well round plate and mixed well. After incubation for 15 minutes at room temperature, 50 μl / well of the sample was dispensed into a 96-well white plate, and 50 μl / well of Luciferase assay reagent (Promega, G7940) was dispensed and mixed well. Incubate for 15 minutes at room temperature, blocking light. After the reaction was completed, measurement was performed using VITORTM X3 equipment. It was confirmed using two donors.

[0238] The results are shown in Figures 9a and 9b.

[0239] As shown in Figures 9a and 9b, the cytotoxicity analysis results confirmed that the M4 form protein complex had superior cytotoxicity compared to the basic form dual antigen target protein complex.

[0240] As shown in Fig. 9a, the graph confirmed that the cytotoxicity of 15E3_ZAAD01M4 increased compared to 15E3_ZAAD01, and in the first donor, the cell viability decreased from about 50% to about 30% in the maximum value, confirming that the cytotoxicity was improved, and in the second donor, the cell viability decreased from about 70% to about 35% in the maximum value, confirming that the cytotoxicity was improved.

[0241] As shown in Fig. 9b, compared to 15E3_ZAAD05, 15E3_ZAAD05M4 showed improved cytotoxicity with a decrease in cell viability from approximately 60% to 35% in the first donor, and improved cytotoxicity with a decrease in cell viability from approximately 85% to 35% in the second donor.

[0242]

[0243] Example 8: Production of various types of dual antigen-targeting protein complexes based on antibodies targeting PSMA.

[0244] Various types of dual antigen targeting protein complexes based on antibodies targeting PSMA were prepared using J591 antibody and affibody (ZAAD01 / ZAAD05) as in Example 1.

[0245] Based on the J591_ZAAD01 / J591_ZAAD05 form, which consists of two types of affibodies for the target antibody J591 of PSMA, a dual antigen-targeting protein complex was produced in the form of a D form with an affibody dimer added to the C-terminus of the heavy chain of the antibody, and an M4 form with an affibody added to both the C-terminus of the heavy chain and light chain of the antibody, and named J591_ZAAD01D / J591_ZAAD05D and J591_ZAAD01M4 / J591_ZAAD05M4, respectively.

[0246] As shown in Figure 10, the SDS-PAGE results confirmed the successful production of each type of dual antigen-target protein complex (reducing conditions in Figure 10). Among the optimized bispecific antibody candidates, a larger-than-normal band was conspicuously observed in J591_ZAAD01D / J591_ZAAD05D (non-reducing conditions in Figure 10). This result was similar to that of the Cetuximab-based antibody.

[0247]

[0248] Example 9: Comparison of CD8 T cell activation abilities of various forms of dual antigen targeting protein complexes based on antibodies targeting PSMA.

[0249] We compared the PSMA-dependent CD8 T cell activation ability using a dual antigen targeting protein complex based on the J591 antibody, a PSMA-specific antibody. CD8 T cell activation tests were performed using LNCap cells, which express PSMA, and MKN45 cells, which do not express PSMA. The day before, 50 μL of anti-CD3 antibody (Invitrogen, 16-0037-85) was coated on a 96-well round plate at a concentration of 3 μg / mL. The next day, the plates were washed three times with 100 μL of sterile PBS. After washing three times with 100 μL of R10 media (RPMI 1640, 10% FBS, 10 mM Hepes), 100 μL of R10 media (RPMI 1640, 10% FBS, 10 mM Hepes) was added, and the plates were blocked at 37°C for 1 hour. Remove the R10 media (RPMI1640, 10% FBS, 10 mM Hepes) from the plate and measure the number of LNCap cells and MKN45 cells to 7 X10 5After dissolving in R10 media to reach 10 / mL, 50 μL was treated on the plate. 50 μL of six types of dual antigen-target protein complexes were treated at 25 nM for 30 minutes. Meanwhile, blood donated from a healthy donor was diluted 1 / 2 with PBS, placed in a Lucosep tube (greiner bio-one, 227290) suspended on Picoll (GE healthcare, 17-1440-12), and centrifuged at 1000 g for 30 minutes. Only the layer of PBMCs on top of Picoll (GE healthcare, 17-1440-12) was recovered. PBMCs were centrifuged at 300 g for 10 minutes using 2% in PBS, washed twice, and the number of PBMCs was measured. CD8 positive T cells were prepared from PBMC using the CD8 isolation kit (Myltenybiotec / 130-096-495). The number of CD8+ T cells was measured and 1.4 X 10 6 After dissolving in R10 media (RPMI 1640, 10% FBS, 10 mM Hepes) to / mL, 50 uL was treated on the plate treated with the dual antigen-target protein complex. After 3 days of treatment, the plate was centrifuged at 2000 RPM for 10 minutes, and the supernatant was collected, and the IFN-gamma measurement kit (BD, 555142) and Granzyme B measurement kit (R&D systems, DY2906-05) were used for each process. The activity level of CD8 T cells was compared through the measurement of IFN-gamma and Granzyme B.

[0250] The results are shown in Fig. 11.

[0251] As shown in Fig. 11, the CD8 T cell activation ability of the dual antigen target protein complex in the D form and M4 form was superior to that of the basic form. It was confirmed that the amounts of secreted IFN-Gamma and GranzyneB increased in J591_ZAAD01D and J591_ZAAD01M4 compared to J591_ZAAD01, and it was also confirmed that the amounts of secreted IFN-Gamma and GranzyneB increased in J591_ZAAD05D and J591_ZAAD05M4 compared to J591_ZAAD05.

Claims

1. A dual antigen-targeting protein complex comprising a first antigen-targeting portion comprising an antibody or an antigen-binding fragment thereof; and a second antigen-targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

2. A dual antigen target protein complex in which an affibody dimer is bound to the C-terminal of the heavy chain of an antibody or an antigen-binding fragment thereof in the first paragraph.

3. A dual antigen target protein complex in which an affibody monomer is bound to each of the C-terminals of the heavy chain and light chain of the antibody or its antigen-binding fragment in paragraph 1.

4. A dual antigen target protein complex in which an affibody dimer is bound to the C-terminal of the light chain of an antibody or an antigen-binding fragment thereof in the first paragraph.

5. A dual antigen target protein complex according to claim 1, wherein the first antigen target site targets EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen); and the second antigen target site targets CD137.

6. A dual antigen target protein complex according to claim 1, wherein the affibody is composed of an amino acid sequence represented by sequence number 1 or sequence number 2.

7. A dual antigen-target protein complex according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of amino acid sequences represented by SEQ ID NO: 3 to SEQ ID NO: 8, comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of amino acid sequences represented by SEQ ID NO: 27 to SEQ ID NO: 32, or comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each consisting of amino acid sequences represented by SEQ ID NO: 51 to SEQ ID NO:

56.

8. A dual antigen target protein complex according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain each composed of the amino acid sequences represented by SEQ ID NO: 9 and SEQ ID NO: 10, a heavy chain and a light chain each composed of the amino acid sequences represented by SEQ ID NO: 33 and SEQ ID NO: 34, or a heavy chain and a light chain each composed of the amino acid sequences represented by SEQ ID NO: 57 and SEQ ID NO:

58.

9. In the first paragraph, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 11 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 12, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 19 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 20, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 35 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 36, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 43 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 44, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 59 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 60, or a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 67 is bound and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 68 A dual antigen target protein complex comprising a light chain.

10. In the first paragraph, the dual antigen target protein complex comprises a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 13 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 14, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 21 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 22, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 37 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 38, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 45 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 46, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 61 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 62, or a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 69 and an amino acid sequence represented by SEQ ID NO:

70. A dual antigen targeting protein complex comprising a light chain consisting of a sequence.

11. In the first paragraph, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 15 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 16 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 23 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 24 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 39 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 40 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 47 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 48 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 63 is bound and an affibody consisting of an amino acid sequence represented by SEQ ID NO. 64 A dual antigen target protein complex comprising a light chain to which monomers are bound, or a heavy chain to which an affibody monomer comprising an amino acid sequence represented by SEQ ID NO: 71 is bound and a light chain to which an affibody monomer comprising an amino acid sequence represented by SEQ ID NO: 72 is bound.

12. In the first paragraph, the dual antigen target protein complex comprises a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 17 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 18 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 25 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 26 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 41 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 42 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 49 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 50 bound to it, a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 65 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 66 bound to it, or a heavy chain having an amino acid sequence represented by SEQ ID NO: 73 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 74 bound to it. A dual antigen targeting protein complex comprising a dimer-bound light chain.

13. A nucleic acid molecule comprising a nucleotide sequence encoding a dual antigen target protein complex of any one of claims 1 to 12.

14. A recombinant vector comprising the nucleic acid molecule of item 13.

15. A host cell containing the recombinant vector of paragraph 14.

16. A pharmaceutical composition for preventing or treating cancer, comprising a dual antigen-targeting protein complex comprising an EFGR (Epidermal Growth Factor Receptor) or PSMA (Prostate-Specific Membrane Antigen) targeting portion comprising an antibody or an antigen-binding fragment thereof; and a CD137 targeting portion comprising an affibody bound to the antibody or an antigen-binding fragment thereof.

17. A pharmaceutical composition for preventing or treating cancer, wherein the dual antigen target protein complex is a pharmaceutical composition in which an affibody dimer is bound to the C-terminal of the heavy chain of an antibody or an antigen-binding fragment thereof.

18. A pharmaceutical composition for preventing or treating cancer, wherein the dual antigen target protein complex comprises an affibody monomer bound to the C-terminus of each of the heavy chain and light chain of an antibody or an antigen-binding fragment thereof.

19. A pharmaceutical composition for preventing or treating cancer, wherein the dual antigen target protein complex is a pharmaceutical composition in which an affibody dimer is bound to the C-terminal of a light chain of an antibody or an antigen-binding fragment thereof.

20. In claim 16, the dual antigen target protein complex comprises a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 11 and a light chain bound to an amino acid sequence represented by SEQ ID NO: 12, a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 19 and a light chain bound to an amino acid sequence represented by SEQ ID NO: 20, a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 35 and a light chain bound to an amino acid sequence represented by SEQ ID NO: 36, a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 43 and a light chain bound to an amino acid sequence represented by SEQ ID NO: 44, a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 59 and a light chain bound to an amino acid sequence represented by SEQ ID NO: 60, or a heavy chain bound to an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 67 and an amino acid sequence represented by SEQ ID NO:

68. A pharmaceutical composition for preventing or treating cancer, comprising a light chain consisting of a sequence.

21. In claim 16, the dual antigen target protein complex comprises a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 13 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 14, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 21 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 22, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 37 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 38, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 45 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 46, a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 61 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 62, or a heavy chain bound to an affibody dimer consisting of an amino acid sequence represented by SEQ ID NO: 69 and an amino acid sequence represented by SEQ ID NO:

70. A pharmaceutical composition for preventing or treating cancer, comprising a light chain consisting of a sequence.

22. In claim 16, the dual antigen target protein complex comprises a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 15 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 16 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 23 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 24 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 39 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 40 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 47 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 48 is bound, a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 63 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO. 64 is bound. A pharmaceutical composition for preventing or treating cancer, comprising a light chain to which an affibody monomer is bound, or a heavy chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 71 is bound and a light chain to which an affibody monomer consisting of an amino acid sequence represented by SEQ ID NO: 72 is bound.

23. In claim 16, the dual antigen target protein complex comprises a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 17 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 18 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 25 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 26 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 41 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 42 bound to it, a light chain having a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 49 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 50 bound to it, a heavy chain composed of an amino acid sequence represented by SEQ ID NO: 65 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 66 bound to it, or a heavy chain having an amino acid sequence represented by SEQ ID NO: 73 and an affibody dimer composed of an amino acid sequence represented by SEQ ID NO: 74 bound to it. A pharmaceutical composition for preventing or treating cancer, comprising a light chain to which a dimer is bound.

Citation Information

Patent Citations

  • Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity

    US4554101A

  • Process for the purification of recombinant polypeptides

    WO1988007085A1

  • Leader sequences for the production of recombinant proteins

    WO1988007086A1

  • Targeted multifunctional proteins

    WO1988009344A1

  • Unmanned automated nonfaced product sales system

    KR102550009B1